✨@myESMO Presidential Symposium Spotlight✨: Head-to-head vs durvalumab + chemo, ivonescimab + gemcitabine/cisplatin improved OS (HR, 0.75), PFS (HR, 0.61), and ORR in first-line advanced biliary tract cancer in the phase 3 HARMONi-GI1 trial.

Full #ESMO26 data: https://www.onclive.com/view/ivonescimab-plus-chemotherapy-improves-os-vs-durvalumab-plus-chemotherapy-in-first-line-biliary

#medtwitter #oncology